TG Therapeutics Inc (TGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
TG Therapeutics Inc (TGTX) Stock Forecast
Analysts expect TG Therapeutics (TGTX) to earn $1.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $999.31M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 6 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 12.5% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 161.6% and revenue estimates rise 34.1%.
- Fiscal year ending Dec 31, 2026
- $1.12
- EPS consensus, revenue $999.31M
- Fiscal year ending Dec 31, 2027
- $2.93
- EPS consensus, revenue $1.34B
- Next report
- Jan 11, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.12 | $1.12 to $1.12 | 1 | $999.31M | $980.00M to $1.01B | 7 |
| Dec 31, 2027 | $2.93 | $2.16 to $3.49 | 3 | $1.34B | $1.22B to $1.42B | 8 |
Quarterly Estimates
The EPS consensus rises from $0.56 for the quarter ending Dec 31, 2026 to $0.60 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.56 | $0.32 to $0.72 | 10 | $294.51M | $261.56M to $315.00M | 10 |
| Mar 31, 2027 | $0.60 | $0.60 to $0.60 | 1 | $298.03M | $283.00M to $314.40M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 12.0% from $1.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.12 | $0.95 | $0.95 | $0.95 | $1.00 | +12.4% |
| Fiscal year ending Dec 31, 2027 | $2.93 | $2.71 | $2.71 | $2.97 | $3.13 | -6.4% |
| Quarter ending Mar 31, 2027 | $0.60 | $0.45 | $0.45 | $0.45 | $0.45 | +33.3% |
Frequently Asked Questions About TGTX
What is the TGTX stock forecast?
Consensus analyst estimates put TG Therapeutics's EPS at $1.12 for the fiscal year ending Dec 31, 2026, on revenue of $999.31M. The consensus rating from 8 analysts is Buy.
How do analysts rate TGTX stock?
Of 8 analysts covering TG Therapeutics, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TGTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.12, with estimates from $1.12 to $1.12 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.93, with estimates from $2.16 to $3.49 from 3 analysts.
What revenue do analysts expect from TG Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $999.31M, with estimates from $980.00M to $1.01B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.34B, with estimates from $1.22B to $1.42B.
How many analysts cover TGTX?
8 analysts rate TG Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
TGTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors